Latest Administration News

Page 154 of 164
Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.
Ada Torres
Ada Torres
30 Jan 2025
ioneer Ltd’s December 2024 quarterly cash flow report reveals ongoing cash outflows from operations and investing, with nearly $4.5 million spent this quarter but a solid cash reserve providing a runway of almost five quarters.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.
Ada Torres
Ada Torres
30 Jan 2025
Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.
Ada Torres
Ada Torres
30 Jan 2025
NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.
Victor Sage
Victor Sage
30 Jan 2025
Imagion Biosystems has secured a AU$3 million capital injection and resumed its collaboration with Siemens, setting the stage to prioritize FDA filings and advance its MagSense® HER2 breast cancer imaging program.
Ada Torres
Ada Torres
30 Jan 2025
Perpetual Limited's Q2 FY25 update reveals a 3.6% rise in Assets Under Management to A$230.2 billion, buoyed by currency tailwinds despite net outflows and market headwinds. Corporate Trust and Wealth Management also posted modest growth, setting the stage for the upcoming half-year results.
Claire Turing
Claire Turing
30 Jan 2025
LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.
Ada Torres
Ada Torres
30 Jan 2025
Top End Energy Limited reported a net cash outflow in its December quarter, reducing its cash reserves to $2.76 million and leaving funding for just over two and a half quarters. The company’s cash flow dynamics highlight the ongoing financial pressures typical in early-stage oil and gas exploration.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Galileo Mining Ltd’s latest quarterly cash flow report reveals a $706,000 net cash decrease amid ongoing exploration spending, while maintaining a strong cash position of $11.3 million.
Maxwell Dee
Maxwell Dee
30 Jan 2025
NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Anson Resources secured key approvals to expand drilling at its Utah lithium projects, reported a maiden resource at its Western Australia base metals deposit, and raised $2.3 million in an oversubscribed share purchase plan.
Maxwell Dee
Maxwell Dee
30 Jan 2025